Heartflow (NASDAQ:HTFL) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Heartflow (NASDAQ:HTFL) in a research note published on Monday morning,Benzinga reports. They currently have a $40.00 target price on the stock.

Several other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company began coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price for the company. Stifel Nicolaus upped their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Heartflow has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Stock Up 0.9%

Shares of HTFL opened at $23.18 on Monday. The business’s fifty day moving average is $28.29 and its 200 day moving average is $30.93. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22. The stock has a market cap of $1.97 billion and a P/E ratio of -12.81.

Insider Activity

In other news, Director Jeffrey C. Lightcap purchased 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were bought at an average cost of $26.34 per share, with a total value of $1,053,600.00. Following the completion of the transaction, the director directly owned 40,000 shares of the company’s stock, valued at approximately $1,053,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Campbell Rogers sold 65,153 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the transaction, the insider owned 76,034 shares in the company, valued at approximately $1,862,072.66. This trade represents a 46.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,104,837 shares of company stock worth $58,761,759.

Hedge Funds Weigh In On Heartflow

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP grew its holdings in shares of Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after acquiring an additional 1,014,006 shares in the last quarter. Baillie Gifford & Co. bought a new stake in Heartflow during the third quarter worth $101,182,000. Bamco Inc. NY boosted its position in Heartflow by 86.2% in the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after purchasing an additional 1,066,371 shares during the last quarter. Schusterman Interests LLC bought a new position in Heartflow in the 3rd quarter valued at $65,274,000. Finally, Capricorn Investment Group LLC bought a new position in Heartflow in the 4th quarter valued at $48,178,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.